Rational design of novel HIV-1 entry inhibitors by RANTES engineering
- 10 January 2008
- Vol. 26 (24) , 3008-3015
- https://doi.org/10.1016/j.vaccine.2007.12.023
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4Science, 2007
- South Africa's Experience of the Closure of the Cellulose Sulphate Microbicide TrialPLoS Medicine, 2007
- Anti-HIV microbicides: don't forget basic immunologyThe Lancet, 2007
- Recognition of RANTES by Extracellular Parts of the CCR5 ReceptorJournal of Molecular Biology, 2007
- Critical role of the N-loop and β1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activityBiochemical and Biophysical Research Communications, 2006
- Engineered VaginalLactobacillusStrain for Mucosal Delivery of the Human Immunodeficiency Virus Inhibitor Cyanovirin-NAntimicrobial Agents and Chemotherapy, 2006
- Recognition of a CXCR4 Sulfotyrosine by the Chemokine Stromal Cell-derived Factor-1α (SDF-1α/CXCL12)Journal of Molecular Biology, 2006
- The structural biology of type I viral membrane fusionNature Reviews Molecular Cell Biology, 2003
- Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated CleavageThe Journal of Experimental Medicine, 1997
- Peptides from the Amino Terminus of Rantes Cause Chemotaxis of Human T-LymphocytesBiochemical and Biophysical Research Communications, 1995